New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
07:32 EDTAVEOAveo Pharmaceuticals weakness unwarranted, says RBC Capital
RBC Capital believes that the weakness in Aveo's shares is unwarranted, as the firm doesn't think that details about the company's tivozanib treatment shed light on its approvability. RBC Capital thinks that tivozanib's risk-benefit profile is favorable, and it maintains an Outperform rating on the shares.
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:52 EDTAVEOAveo Pharmaceuticals shares recommended by Agora Financial
Agora Financial named Aveo Pharmaceuticals a new buy recommendation with a $57 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use